Chinese General Practice ›› 2023, Vol. 26 ›› Issue (13): 1605-1612.DOI: 10.12114/j.issn.1007-9572.2022.0781
Special Issue: 社区卫生服务最新研究合辑; 老年人群健康最新文章合辑; 用药最新文章合辑; 老年人合理用药专题研究; 老年问题最新文章合辑
• Original Research·Focus on Multimorbidity • Previous Articles Next Articles
Received:
2022-10-28
Revised:
2023-02-18
Published:
2023-05-05
Online:
2023-02-23
Contact:
KONG Lingna
通讯作者:
孔令娜
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0781
步骤 | 策略 |
---|---|
#1 | ("inappropriate prescribing"[MeSH Terms]OR "medication error*"[MeSH Terms])OR("inappropriate prescribing"[Title/Abstract]OR "inappropriate prescription*"[Title/Abstract]OR "inappropriate medication*"[Title/Abstract]OR "inappropriate medicine*"[Title/Abstract]OR "inappropriate drug*"[Title/Abstract]OR "irrational prescribing*"[Title/Abstract]OR "irrational prescription*"[Title/Abstract]OR "high risk prescription*"[Title/Abstract]OR "high risk medication*"[Title/Abstract]OR "unsafe prescribing"[Title/Abstract]OR "unsafe medication*"[Title/Abstract]OR "harmful medication*"[Title/Abstract]OR "harmful drug*"[Title/Abstract]OR "suboptimal prescribing"[Title/Abstract]OR "suboptimal medication*"[Title/Abstract]OR "overprescribing"[Title/Abstract]OR "over-prescribing"[Title/Abstract]OR "over-prescription"[Title/Abstract]OR "prescription drug misuse"[Title/Abstract]OR "deprescrib*"[Title/Abstract]OR "prescribing patterns"[Title/Abstract]) |
#2 | ("primary health care"[MeSH Terms]OR "general practice"[MeSH Terms]OR "general practitioners"[MeSH Terms] OR "family practice"[MeSH Terms]OR "community health centers"[MeSH Terms]OR "community health services"[MeSH Terms]OR "physicians,family"[MeSH Terms] OR "hospitals,community"[MeSH Terms])OR("family physicians"[Title/Abstract]OR "family practice*"[Title/Abstract]OR "general practice*"[Title/Abstract]OR "general practitioner*"[Title/Abstract]OR "primary care"[Title/Abstract]OR "primary health care"[Title/Abstract]OR "primary medical care"[Title/Abstract]OR "community*"[Title/Abstract]OR "home*"[Title/Abstract]OR "general population"[Title/Abstract]OR "health station"[Title/Abstract]) |
#3 | ("aged"[MeSH Terms])OR("elder*"[Title/Abstract] OR "older*"[Title/Abstract]OR "senior*"[Title/Abstract] OR "aging"[Title/Abstract]OR "ageing"[Title/Abstract]OR "aged"[Title/Abstract]OR "geriatric"[Title/Abstract]) |
#4 | "China"[All Fields]OR"Chinese"[All Fields]OR"China"[MeSH Terms] |
#5 | #1 AND #2 AND #3 AND #4 |
Table 1 Strategy for searching in PubMed
步骤 | 策略 |
---|---|
#1 | ("inappropriate prescribing"[MeSH Terms]OR "medication error*"[MeSH Terms])OR("inappropriate prescribing"[Title/Abstract]OR "inappropriate prescription*"[Title/Abstract]OR "inappropriate medication*"[Title/Abstract]OR "inappropriate medicine*"[Title/Abstract]OR "inappropriate drug*"[Title/Abstract]OR "irrational prescribing*"[Title/Abstract]OR "irrational prescription*"[Title/Abstract]OR "high risk prescription*"[Title/Abstract]OR "high risk medication*"[Title/Abstract]OR "unsafe prescribing"[Title/Abstract]OR "unsafe medication*"[Title/Abstract]OR "harmful medication*"[Title/Abstract]OR "harmful drug*"[Title/Abstract]OR "suboptimal prescribing"[Title/Abstract]OR "suboptimal medication*"[Title/Abstract]OR "overprescribing"[Title/Abstract]OR "over-prescribing"[Title/Abstract]OR "over-prescription"[Title/Abstract]OR "prescription drug misuse"[Title/Abstract]OR "deprescrib*"[Title/Abstract]OR "prescribing patterns"[Title/Abstract]) |
#2 | ("primary health care"[MeSH Terms]OR "general practice"[MeSH Terms]OR "general practitioners"[MeSH Terms] OR "family practice"[MeSH Terms]OR "community health centers"[MeSH Terms]OR "community health services"[MeSH Terms]OR "physicians,family"[MeSH Terms] OR "hospitals,community"[MeSH Terms])OR("family physicians"[Title/Abstract]OR "family practice*"[Title/Abstract]OR "general practice*"[Title/Abstract]OR "general practitioner*"[Title/Abstract]OR "primary care"[Title/Abstract]OR "primary health care"[Title/Abstract]OR "primary medical care"[Title/Abstract]OR "community*"[Title/Abstract]OR "home*"[Title/Abstract]OR "general population"[Title/Abstract]OR "health station"[Title/Abstract]) |
#3 | ("aged"[MeSH Terms])OR("elder*"[Title/Abstract] OR "older*"[Title/Abstract]OR "senior*"[Title/Abstract] OR "aging"[Title/Abstract]OR "ageing"[Title/Abstract]OR "aged"[Title/Abstract]OR "geriatric"[Title/Abstract]) |
#4 | "China"[All Fields]OR"Chinese"[All Fields]OR"China"[MeSH Terms] |
#5 | #1 AND #2 AND #3 AND #4 |
作者 | 发表年份(年) | 研究类型 | 地区 | 样本量 | 年龄(岁) | 样本中男性占比(%) | PIM评估工具 | PIM发生率(%) | PIM相关因素 |
---|---|---|---|---|---|---|---|---|---|
赵欢等[ | 2012 | 横断面研究 | 河北省 | 416 | ≥60 | 50.2 | Beers标准(2003版) | 14.7 | — |
李旭琴等[ | 2015 | 横断面研究 | 上海市 | 398 | 60~75 | 44.2 | Beers标准(2012版) | 37.7 | — |
杨楠等[ | 2016 | 横断面研究 | 上海市 | 6 002 | 60~97 | 40.1 | Beers标准(2012版) | 16.0 | ⑦ |
杨晓欧等[ | 2017 | 横断面研究 | 北京市 | 216 | 65~89 | 41.2 | Beers标准(2015版) STOPP标准(2014版) | 26.4 33.8 | — |
陈张勇等[ | 2018 | 横断面研究 | 北京市 | 795 | 65~103 | 49.2 | Beers标准(2015版) STOPP标准(2014版) 中国PIM标准(2015版) | 25.4 18.5 28.9 | — |
栗芳等[ | 2018 | 横断面研究 | 北京市 | 332 | 65~80 | 56.6 | Beers标准(2015版) | 17.5 | — |
唐志华[ | 2018 | 横断面研究 | 浙江省 | 300 | ≥60 | 32.7 | Beers标准(2015版) | 36.3 | — |
刘葳等[ | 2020 | 横断面研究 | 上海市 | 360 | 65~96 | 50.3 | Beers标准(2015版) STOPP标准(2014版) | 15.8 22.2 | ①、②、③、④、⑤、⑥、⑦ |
刘晓瑞等[ | 2020 | 横断面研究 | 北京市 | 215 | 60~90 | 31.2 | Beers标准(2019版) 中国PIM标准(2017版) | 30.7 24.7 | — |
黄琦岚[ | 2020 | 横断面研究 | 山西省 | 476 | ≥60 | 43.5 | Beers标准(2015版) | 67.2 | ①、②、③、④、⑤、⑥、⑦ |
李雪冰等[ | 2020 | 横断面研究 | 北京市 | 264 | 62~95 | 58.3 | Beers标准(2019版) 中国PIM标准(2017版) | 39.0 28.4 | ①、②、④、⑤、⑥ |
章陈怡等[ | 2020 | 横断面研究 | 上海市 | 968 | ≥65 | 51.3 | Beers标准(2015版) | 32.7 | ①、②、⑥、⑦ |
单青等[ | 2021 | 横断面研究 | 北京市 | 562 | 65~97 | 33.3 | 中国PIM标准(2017版) | 69.6 | ①、②、③、④、⑦ |
顾乐乐等[ | 2021 | 横断面研究 | 上海市 | 300 | 61~88 | 52.3 | 中国PIM标准(2017版) | 19.3 | ①、②、⑥、⑦ |
杜琳娜[ | 2021 | 横断面研究 | 陕西省 | 319 | ≥60 | 40.4 | 中国PIM标准(2017版) | 58.0 | ①、②、③、④、⑤ |
周茜等[ | 2021 | 横断面研究 | 青海省 | 530 | ≥65 | 53.8 | STOPP标准(2014版) | 32.6 | ①、②、④、⑤、⑥、⑦ |
栗芳等[ | 2022 | 横断面研究 | 北京市 | 943 | 60~79 | 48.5 | 中国PIM标准(2017版) | 31.3 | — |
耿佳音等[ | 2022 | 横断面研究 | 北京市 | 815 | ≥60 | 37.4 | Beers标准(2019版) 中国PIM标准(2017版) | 32.6 22.3 | ①、②、⑥、⑦ |
田艳等[ | 2022 | 横断面研究 | 北京市 | 312 | 65~93 | 42.8 | STOPP标准(2014版) 中国PIM标准(2017版) | 35.9 29.7 | ①、②、④、⑥、⑦ |
王思蒙[ | 2022 | 横断面研究 | 安徽省 | 422 | 62~101 | 46.2 | 中国PIM标准(2017版) | 64.0 | — |
HUANG等[ | 2020 | 横断面研究 | 湖南省 | 1 874 | 65~102 | 80.0 | Beers标准(2019版) 中国PIM标准(2017版) | 35.0 50.6 | ①、②、⑥、⑦ |
LI等[ | 2021 | 横断面研究 | 江苏省 | 8 235 | 65~103 | 51.9 | Beers标准(2019版) 中国PIM标准(2017版) | 32.2 37.1 | ①、②、⑥、⑦ |
SU等[ | 2022 | 横断面研究 | 北京市 | 506 214 | 65~105 | 49.9 | Beers标准(2015版) | 38.1 | ①、② |
ZENG等[ | 2022 | 横断面研究 | 北京市 | 508 | ≥65 | 46.7 | Beers标准(2015版) Beers标准(2019版) STOPP标准(2014版) | 34.7 42.5 73.2 | ①、②、③、④、⑤、⑥、⑦ |
Table 2 Basic characteristics of included studies
作者 | 发表年份(年) | 研究类型 | 地区 | 样本量 | 年龄(岁) | 样本中男性占比(%) | PIM评估工具 | PIM发生率(%) | PIM相关因素 |
---|---|---|---|---|---|---|---|---|---|
赵欢等[ | 2012 | 横断面研究 | 河北省 | 416 | ≥60 | 50.2 | Beers标准(2003版) | 14.7 | — |
李旭琴等[ | 2015 | 横断面研究 | 上海市 | 398 | 60~75 | 44.2 | Beers标准(2012版) | 37.7 | — |
杨楠等[ | 2016 | 横断面研究 | 上海市 | 6 002 | 60~97 | 40.1 | Beers标准(2012版) | 16.0 | ⑦ |
杨晓欧等[ | 2017 | 横断面研究 | 北京市 | 216 | 65~89 | 41.2 | Beers标准(2015版) STOPP标准(2014版) | 26.4 33.8 | — |
陈张勇等[ | 2018 | 横断面研究 | 北京市 | 795 | 65~103 | 49.2 | Beers标准(2015版) STOPP标准(2014版) 中国PIM标准(2015版) | 25.4 18.5 28.9 | — |
栗芳等[ | 2018 | 横断面研究 | 北京市 | 332 | 65~80 | 56.6 | Beers标准(2015版) | 17.5 | — |
唐志华[ | 2018 | 横断面研究 | 浙江省 | 300 | ≥60 | 32.7 | Beers标准(2015版) | 36.3 | — |
刘葳等[ | 2020 | 横断面研究 | 上海市 | 360 | 65~96 | 50.3 | Beers标准(2015版) STOPP标准(2014版) | 15.8 22.2 | ①、②、③、④、⑤、⑥、⑦ |
刘晓瑞等[ | 2020 | 横断面研究 | 北京市 | 215 | 60~90 | 31.2 | Beers标准(2019版) 中国PIM标准(2017版) | 30.7 24.7 | — |
黄琦岚[ | 2020 | 横断面研究 | 山西省 | 476 | ≥60 | 43.5 | Beers标准(2015版) | 67.2 | ①、②、③、④、⑤、⑥、⑦ |
李雪冰等[ | 2020 | 横断面研究 | 北京市 | 264 | 62~95 | 58.3 | Beers标准(2019版) 中国PIM标准(2017版) | 39.0 28.4 | ①、②、④、⑤、⑥ |
章陈怡等[ | 2020 | 横断面研究 | 上海市 | 968 | ≥65 | 51.3 | Beers标准(2015版) | 32.7 | ①、②、⑥、⑦ |
单青等[ | 2021 | 横断面研究 | 北京市 | 562 | 65~97 | 33.3 | 中国PIM标准(2017版) | 69.6 | ①、②、③、④、⑦ |
顾乐乐等[ | 2021 | 横断面研究 | 上海市 | 300 | 61~88 | 52.3 | 中国PIM标准(2017版) | 19.3 | ①、②、⑥、⑦ |
杜琳娜[ | 2021 | 横断面研究 | 陕西省 | 319 | ≥60 | 40.4 | 中国PIM标准(2017版) | 58.0 | ①、②、③、④、⑤ |
周茜等[ | 2021 | 横断面研究 | 青海省 | 530 | ≥65 | 53.8 | STOPP标准(2014版) | 32.6 | ①、②、④、⑤、⑥、⑦ |
栗芳等[ | 2022 | 横断面研究 | 北京市 | 943 | 60~79 | 48.5 | 中国PIM标准(2017版) | 31.3 | — |
耿佳音等[ | 2022 | 横断面研究 | 北京市 | 815 | ≥60 | 37.4 | Beers标准(2019版) 中国PIM标准(2017版) | 32.6 22.3 | ①、②、⑥、⑦ |
田艳等[ | 2022 | 横断面研究 | 北京市 | 312 | 65~93 | 42.8 | STOPP标准(2014版) 中国PIM标准(2017版) | 35.9 29.7 | ①、②、④、⑥、⑦ |
王思蒙[ | 2022 | 横断面研究 | 安徽省 | 422 | 62~101 | 46.2 | 中国PIM标准(2017版) | 64.0 | — |
HUANG等[ | 2020 | 横断面研究 | 湖南省 | 1 874 | 65~102 | 80.0 | Beers标准(2019版) 中国PIM标准(2017版) | 35.0 50.6 | ①、②、⑥、⑦ |
LI等[ | 2021 | 横断面研究 | 江苏省 | 8 235 | 65~103 | 51.9 | Beers标准(2019版) 中国PIM标准(2017版) | 32.2 37.1 | ①、②、⑥、⑦ |
SU等[ | 2022 | 横断面研究 | 北京市 | 506 214 | 65~105 | 49.9 | Beers标准(2015版) | 38.1 | ①、② |
ZENG等[ | 2022 | 横断面研究 | 北京市 | 508 | ≥65 | 46.7 | Beers标准(2015版) Beers标准(2019版) STOPP标准(2014版) | 34.7 42.5 73.2 | ①、②、③、④、⑤、⑥、⑦ |
作者 | ① | ② | ③ | ④ | ⑤ | ⑥ | ⑦ | ⑧ | ⑨ | ⑩ | ⑪ | 总分(分) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
赵欢等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
李旭琴等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杨楠等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杨晓欧等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
陈张勇等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
栗芳等[ | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 5 |
唐志华[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 7 |
刘葳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
刘晓瑞等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
黄琦岚[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 7 |
李雪冰等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
章陈怡等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
单青等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
顾乐乐等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杜琳娜[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
周茜等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
栗芳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
耿佳音等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
田艳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
王思蒙[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
HUANG等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
LI等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
SU等[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
ZENG等[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
Table 3 Risk of bias assessment of included studies
作者 | ① | ② | ③ | ④ | ⑤ | ⑥ | ⑦ | ⑧ | ⑨ | ⑩ | ⑪ | 总分(分) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
赵欢等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
李旭琴等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杨楠等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杨晓欧等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
陈张勇等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
栗芳等[ | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 5 |
唐志华[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 7 |
刘葳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
刘晓瑞等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
黄琦岚[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 7 |
李雪冰等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
章陈怡等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
单青等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
顾乐乐等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
杜琳娜[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
周茜等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
栗芳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
耿佳音等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
田艳等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
王思蒙[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
HUANG等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
LI等[ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
SU等[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
ZENG等[ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
亚组 | 纳入研究数(项) | 异质性检验 | 效应模型 | PIM发生率(95%CI)(%) | |
---|---|---|---|---|---|
P值 | I2(%) | ||||
评估工具 | |||||
Beers标准 | 17[ | <0.001 | 99.4 | 随机 | 31.9(26.7,37.1) |
中国PIM标准 | 12[ | <0.001 | 98.7 | 随机 | 38.7(31.1,46.3) |
STOPP标准 | 6[ | <0.001 | 99.1 | 随机 | 36.0(18.4,53.7) |
样本中男性占比(%) | |||||
<50 | 15[ | <0.001 | 99.4 | 随机 | 38.1(32.4,43.9) |
≥50 | 9[ | <0.001 | 98.0 | 随机 | 29.1(24.4,33.8) |
地理区域 | |||||
北方 | 15[ | <0.001 | 98.6 | 随机 | 35.6(30.8,40.5) |
南方 | 9[ | <0.001 | 99.4 | 随机 | 33.2(26.3,40.1) |
文献发表时间(年) | |||||
2012—2019 | 7[ | <0.001 | 96.0 | 随机 | 25.2(20.4,30.1) |
2020—2022 | 17[ | <0.001 | 98.5 | 随机 | 38.4(35.3,41.6) |
Table 4 Subgroup analysis of the prevalence of potentially inappropriate medication in community-dwelling Chinese older adults
亚组 | 纳入研究数(项) | 异质性检验 | 效应模型 | PIM发生率(95%CI)(%) | |
---|---|---|---|---|---|
P值 | I2(%) | ||||
评估工具 | |||||
Beers标准 | 17[ | <0.001 | 99.4 | 随机 | 31.9(26.7,37.1) |
中国PIM标准 | 12[ | <0.001 | 98.7 | 随机 | 38.7(31.1,46.3) |
STOPP标准 | 6[ | <0.001 | 99.1 | 随机 | 36.0(18.4,53.7) |
样本中男性占比(%) | |||||
<50 | 15[ | <0.001 | 99.4 | 随机 | 38.1(32.4,43.9) |
≥50 | 9[ | <0.001 | 98.0 | 随机 | 29.1(24.4,33.8) |
地理区域 | |||||
北方 | 15[ | <0.001 | 98.6 | 随机 | 35.6(30.8,40.5) |
南方 | 9[ | <0.001 | 99.4 | 随机 | 33.2(26.3,40.1) |
文献发表时间(年) | |||||
2012—2019 | 7[ | <0.001 | 96.0 | 随机 | 25.2(20.4,30.1) |
2020—2022 | 17[ | <0.001 | 98.5 | 随机 | 38.4(35.3,41.6) |
项目 | 纳入研究数(项) | 异质性检验 | 效应模型 | OR (95%CI) | Z值 | P值 | |
---|---|---|---|---|---|---|---|
P值 | I2(%) | ||||||
性别男 | 11[ | 0.301 | 13.9 | 固定 | 0.986(0.936,1.039) | 0.53 | 0.599 |
年龄≥75岁 | 6[ | <0.001 | 78.6 | 随机 | 1.261(1.074,1.481) | 2.84 | 0.005 |
有配偶 | 4[ | 0.524 | 0 | 固定 | 0.921(0.788,1.076) | 1.04 | 0.297 |
文化程度为初中及以下 | 6[ | 0.287 | 18.8 | 固定 | 1.060(0.926,1.214) | 0.84 | 0.399 |
独居 | 5[ | 0.932 | 0 | 固定 | 1.114(0.862,1.441) | 0.83 | 0.408 |
合并多病(≥5种) | 3[ | <0.001 | 92.6 | 随机 | 3.287(1.405,7.691) | 2.74 | 0.006 |
用药数量≥5种 | 7[ | <0.001 | 95.7 | 随机 | 1.800(1.305,2.481) | 3.59 | <0.001 |
用药数量≥10种 | 4[ | 0.006 | 76.1 | 随机 | 4.380(2.612,7.347) | 5.60 | <0.001 |
Table 5 Meta-analysis of associated factors of potentially inappropriate medication in community-dwelling Chinese older adults
项目 | 纳入研究数(项) | 异质性检验 | 效应模型 | OR (95%CI) | Z值 | P值 | |
---|---|---|---|---|---|---|---|
P值 | I2(%) | ||||||
性别男 | 11[ | 0.301 | 13.9 | 固定 | 0.986(0.936,1.039) | 0.53 | 0.599 |
年龄≥75岁 | 6[ | <0.001 | 78.6 | 随机 | 1.261(1.074,1.481) | 2.84 | 0.005 |
有配偶 | 4[ | 0.524 | 0 | 固定 | 0.921(0.788,1.076) | 1.04 | 0.297 |
文化程度为初中及以下 | 6[ | 0.287 | 18.8 | 固定 | 1.060(0.926,1.214) | 0.84 | 0.399 |
独居 | 5[ | 0.932 | 0 | 固定 | 1.114(0.862,1.441) | 0.83 | 0.408 |
合并多病(≥5种) | 3[ | <0.001 | 92.6 | 随机 | 3.287(1.405,7.691) | 2.74 | 0.006 |
用药数量≥5种 | 7[ | <0.001 | 95.7 | 随机 | 1.800(1.305,2.481) | 3.59 | <0.001 |
用药数量≥10种 | 4[ | 0.006 | 76.1 | 随机 | 4.380(2.612,7.347) | 5.60 | <0.001 |
[1] |
|
[2] |
王思蒙,张晨,孙雪,等. 社区老年人潜在不适当用药及其应对模式的研究进展[J]. 中国全科医学,2022,25(13):1551-1556. DOI:10.12114/j.issn.1007-9572.2022.0077.
|
[3] |
迟俊婷,牛晓丹,阮海慧,等. 潜在不适当用药对老年人不良健康结局影响的系统评价[J]. 中华护理教育,2020,17(3):268-274. DOI:10.3761/j.issn.1672-9234.2020.03.017.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
曾宪涛,刘慧,陈曦,等. Meta分析系列之四:观察性研究的质量评价工具[J]. 中国循证心血管医学杂志,2012,4(4):297-299. DOI:10.3969/j.1674-4055.2012.04.004.
|
[8] |
朱洁云,高敏,宋秋韵,等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学,2022,25(3):346-353. DOI:10.12114/j.issn.1007-9572.2021.02.083.
|
[9] |
赵欢,薛鹏,刘建秋,等. 基于Beers准则的社区老年慢性病患者潜在性不适当用药调查分析[J]. 中国农村卫生事业管理,2012,32(3):241-243.
|
[10] |
李旭琴,杨惠赟,毛凤飞,等. 新版Beers标准评价社区多病种慢性病老年患者潜在性不适当用药的探索[J]. 世界临床药物,2015,36(9):618-622. DOI:10.13683/j.wph.2015.09.010.
|
[11] |
杨楠,管璐艳,郑晓栋,等. 真如社区老年高血压合并糖尿病患者多重用药现状调查[J]. 药物流行病学杂志,2016,25(5):306-308.
|
[12] |
杨晓欧,庄宁,张琳,等. Beers标准和STOPP标准在社区老年患者潜在不适当用药中的评估作用[J]. 临床合理用药杂志,2017,10(21):95-97.
|
[13] |
陈张勇,刘利刚,吐达洪,等. 基于3种标准的社区老年患者潜在不适当用药评估[J]. 中国新药与临床杂志,2018,37(12):700-706. DOI:10.14109/j.cnki.xyylc.2018.12.009.
|
[14] |
栗芳,王思铮,石志华,等. 基于2015版Beers标准的社区老年患者用药问题分析[J]. 中国新药与临床杂志,2018,37(3):173-176. DOI:10.14109/j.cnki.xyylc.2018.03.012.
|
[15] |
唐志华. 社区独居与非独居老人不合理用药现状及影响因素比较研究[D]. 杭州:浙江大学,2018.
|
[16] |
刘葳,于德华,金花,等. 社区老年多病共存患者多重用药情况评价研究[J]. 中国全科医学,2020,23(13):1592-1598. DOI:10.12114/j.issn.1007-9572.2020.00.026.
|
[17] |
刘晓瑞,郭桂芳. 北京市社区老年人潜在不适当用药的调查分析[J]. 解放军护理杂志,2020,37(5):30-34. DOI:10.3969/j.issn.1008-9993.2020.05.008.
|
[18] |
黄琦岚. 太原市社区老年慢性病患者用药情况及生命质量评价研究[D]. 晋中:山西中医药大学,2020.
|
[19] |
李雪冰,王鹏. 斋堂社区老年人潜在不适当用药及其相关因素[J]. 中华老年多器官疾病杂志,2020,19(5):340-344. DOI:10.11915/j.issn.1671-5403.2020.05.080.
|
[20] |
章陈怡,潘志刚,陈实,等. 上海社区老年慢性病患者潜在不适当用药情况及影响因素[J]. 中华全科医师杂志,2020,19(4):324-328. DOI:10.3760/cma.j.cn114798-20190718-00547.
|
[21] |
单青,胡波,陈孟莉. 社区老年人潜在不适当用药与衰弱的相关性[J]. 中华老年多器官疾病杂志,2021,20(8):581-585. DOI:10.11915/j.issn.1671-5403.2021.08.121.
|
[22] |
顾乐乐,杨郗. 社区临床药师视角下老年高血压合并糖尿病患者合理用药现况研究[J]. 山西医药杂志,2021,50(5):706-709. DOI:10.3969/j.issn.0253-9926.2021.05.002.
|
[23] |
杜林娜. 老年糖尿病患者潜在不恰当用药与衰弱的关系研究[D]. 西安:西安医学院,2021.
|
[24] |
周茜,汪晓洲,白洁. 青海地区65岁以上老年群体高血压多病共存患者治疗现状调查[J]. 公共卫生与预防医学,2021,32(5):153-156. DOI:10.3969/j.issn.1006-2483.2021.05.036.
|
[25] |
栗芳,陈张勇,吐达洪,等. 基于我国标准社区老年患者潜在不适当用药分析[J]. 临床药物治疗杂志,2022,20(6):58-62. DOI:10.3969/j.issn.1672-3384.2022.06.011.
|
[26] |
耿佳音,黄亚芳,刘艳丽. 老年患者社区门诊潜在不适当处方影响因素分析[J]. 中国全科医学,2022,25(16):1969-1977. DOI:10.12114/j.issn.1007-9572.2022.0164.
|
[27] |
田艳,周涛,丁林,等. 北京市东城区社区老年患者潜在不适当用药和处方遗漏问题调查分析[J]. 医药导报,2022,41(8):1207-1212. DOI:3870/j.issn.1004-0781.2022.08.022.
|
[28] |
王思蒙. 社区老年轻度认知障碍者衰弱与其亚型分布现状及影响因素分析[D]. 湖州:湖州师范学院,2022.
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
侯凯旋,邢晓璇,闫素英. 中国老年门诊患者潜在不适当用药现状系统评价[J]. 临床药物治疗杂志,2017,15(11):26-30. DOI:10.3969/j.issn.1672-3384.2017.11.006.
|
[36] |
中国老年保健医学研究会老年合理用药分会,中华医学会老年医学分会,中国药学会老年药学专业委员会,等. 中国老年人潜在不适当用药判断标准(2017年版)[J]. 药物不良反应杂志,2018,20(1):2-8. DOI:10.3760/cma.j.issn.1008-5734.2018.01.002.
|
[37] |
舒冰,刘玉龙,姜玲. 老年人潜在不适当用药评估标准研究进展[J]. 中国医院药学杂志,2019,39(18):1905-1910. DOI:10.13286/j.cnki.chinhosppharmacyj.2019.18.20.
|
[38] |
廖雅慧,郎驿天,林燕,等. 常用老年人潜在不适当用药判断标准比较[J]. 中国药房,2022,33(9):1131-1135. DOI:10.6039/j.issn.1001-0408.2022.09.18.
|
[39] |
|
[40] |
李荔,李莎,卫芸,等. 社区老年人多重用药率及其相关因素的系统综述[J]. 中国全科医学,2021,24(25):3161-3170. DOI:10.12114/j.issn.1007-9572.2021.00.204.
|
[41] |
|
[42] |
|
[43] |
|
[1] | XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822. |
[2] | LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778. |
[3] | QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431. |
[4] | ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455. |
[5] | JI Bing, JIANG Dudu, CHEN Chen, ZHENG Yanling, SHI Jianwei, FANG Lizheng, DU Xueping. Constructing a Comprehensive Community Clinical Pathway for Herpes Zoster under Graded Treatment Framework [J]. Chinese General Practice, 2025, 28(25): 3110-3118. |
[6] | YU Wenhua, LI Jianguo, DUAN Wenyan, GAO Xuyan, LI Xiaxia, ZHANG Zilong, ZHANG Li, MA Lina. Reliability and Validity of the Function Impairment Screening Tool among Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(24): 3000-3004. |
[7] | LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999. |
[8] | JIANG Shihua, ZHU Zheng, REN Yingying, ZHU Yaolei, WANG Yue, GAO Xibin. Meta Analysis of the Prevalence and Risk Factors of Myopia in Chinese Children and Adolescents [J]. Chinese General Practice, 2025, 28(24): 3043-3052. |
[9] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
[10] | WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940. |
[11] | LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933. |
[12] | SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, MA Qing. Association between Body Mass Index and Mortality among Older Chinese: a Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2791-2797. |
[13] | SHI Jiarui, WANG Zili, ZHANG Xueqing, SONG Yulei, XU Guihua, BAI Yamei. The Current Status of Initial Cognitive Screening Services in Community-based Cognitive Services Centers in Nanjing [J]. Chinese General Practice, 2025, 28(22): 2784-2790. |
[14] | LIU Meixia, YIN Jinnian, WU Mei, YANG Xing, ZHOU Quanxiang, YANG Jingyuan. Impact of Body Mass Index on the Association of Triglyceride Glucose Index with Cognitive Function: a Cross-sectional Study in Rural Older Adults in Guizhou Province [J]. Chinese General Practice, 2025, 28(22): 2806-2812. |
[15] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||